In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer ...

We recently published a list of 11 Best Innovative Stocks to Buy According to Analysts. In this article, we are going to take ...

Franklin Resources trimmed its Pfizer stake by a smidge, selling just 25,315 shares—but when you’ve got over 16 million, ...

We put performance trends for stocks, sectors, bonds, and funds into perspective, and offer outlooks for the next quarter.

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

StoneX Group clearly didn’t skip leg day—it just bulked up its Pfizer holdings by a massive 43.5% in Q4, scooping up over ...

Nurix Therapeutics, Inc.’s NRIX share price has dipped by 11.87%, which has investors questioning if this is right time to buy.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 10.67%, which has investors questioning if this is right time ...

With its stock down 5.4% over the past month, it is easy to disregard Pfizer (NYSE:PFE). We, however decided to ...